However, a recent phase II clinical study in IPF using the LOXL2 specific antibody Simtuzumab was not able to show significant improvement of the respective endpoints22, raising the possibility that sole targeting of LOXL2 might not be sufficient. The gene discussed is LOXL2; the disease is idiopathic pulmonary fibrosis.